As a result, combinations of CDH3, LFNG, and PLAU were significantly associated with overall survival (log-rank test p-value: 2.376 × 10−5; Fig. 6) compared to other protein combinations and cancers (e.g. hepatocellular carcinoma, colorectal adenocarcinoma, and lung adenocarcinoma; Supplemental Figure). This evidence concerns the gene PLAU and hepatocellular carcinoma.